Compare Enact Holdings Inc (ACT) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs BioNano Genomics Inc — how do they compare? Enact Holdings Inc trades at $49.93 (market cap $6.75B), while BioNano Genomics Inc trades at $1.17 (market cap $13.66M). The key difference: Enact Holdings Inc is far larger — about 494.1× BioNano Genomics Inc's market cap, and Enact Holdings Inc pays a 1.95% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| ACT | BNGO | |
|---|---|---|
Market Cap | $6.75B | $13.66M |
Sector | Technology | Health |
52-Week High | $49.12 | $4.92 |
52-Week Low | $34.93 | $1.06 |
Enterprise Value | $7.05B | $16.26M |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
